The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Angiogenesis in the Infarcted Myocardium
Open accessAbstract
SIGNIFICANCE: Proangiogenic therapy appeared a promising strategy for the treatment of patients with acute myocardial infarction (MI), as de novo formation of microvessels, has the potential to salvage ischemic myocardium at early stages after MI, and is also essential to prevent the transition to heart failure through the control of cardiomyocyte hypertrophy and contractility. RECENT ADVANCES: Exciting preclinical studies evaluating proangiogenic therapies for MI have prompted the initiation of numerous clinical trials based on protein or gene transfer delivery of growth factors and administration of stem/progenitor cells, mainly from bone marrow origin. Nonetheless, these clinical trials showed mixed results in patients with acute MI. CRITICAL ISSUES: Even though methodological caveats, such as way of delivery for angiogenic growth factors (e.g., protein vs. gene transfer) and stem/progenitor cells or isolation/culture procedure for regenerative cells might partially explain the failure of such trials, it appears that delivery of a single growth factor or cell type does not support angiogenesis sufficiently to promote cardiac repair. FUTURE DIRECTIONS: Optimization of proangiogenic therapies might include stimulation of both angiogenesis and vessel maturation and/or the use of additional sources of stem/progenitor cells, such as cardiac progenitor cells. Experimental unraveling of the mechanisms of angiogenesis, vessel maturation, and endothelial cell/cardiomyocyte cross talk in the ischemic heart, analysis of emerging pathways, as well as a better understanding of how cardiovascular risk factors impact endogenous and therapeutically stimulated angiogenesis, would undoubtedly pave the way for the development of novel and hopefully efficient angiogenesis targeting therapeutics for the treatment of acute MI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Nahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.-L., Libby, P., Weissleder, R., & Pittet, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070885 · Cited by 2,300
Cao, R., Bråkenhielm, E., Pawliuk, R., Wariaro, D., Post, M. J., Wahlberg, E., Leboulch, P., & Cao, Y. (2003) · Nature Medicine · doi:10.1038/nm848 · Cited by 721
Caporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G. B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.952325 · Cited by 397
Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., & Thyberg, J. (2004) · Circulation Research · doi:10.1161/01.res.0000118600.91698.bb · Cited by 324
Lu, H., Xu, X., Zhang, M., Cao, R., Bråkenhielm, E., Li, C., Lin, H., Yao, G., Sun, H., Qi, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704966104 · Cited by 107 · cited 2×
“As previously mentioned in this review, combined administration of an angiogenic and an arteriogenic growth factor, namely FGF-2 and PDGF-BB, synergistically enhances angiogenesis in the ischemic heart (70), but this concept is also relevant to cell-based therapy.”
Cited by
Hydrogel‐Based Growth Factor Delivery Platforms: Strategies and Recent Advances
Shan, B., & Wu, F. (2024) · Advanced Materials · doi:10.1002/adma.202210707 · Cited by 430
Gong, M., Yu, B., Wang, J., Wang, Y., Liu, M., Paul, C., Millard, R. W., Xiao, D.-S., Ashraf, M., & Xu, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16778 · Cited by 399
Inflammation and fibrosis in murine models of heart failure
Bacmeister, L., Schwarzl, M., Warnke, S., Stoffers, B., Blankenberg, S., Westermann, D., & Lindner, D. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0722-5 · Cited by 382
Li, Y., Chen, X., Jin, R., Chen, L., Dang, M., Cao, H., Dong, Y., Cai, B., Bai, G., Gooding, J. J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6740 · Cited by 256
Xue, C., Shen, Y., Li, X., Li, B., Zhao, S., Gu, J., Chen, Y., Ma, B., Wei, J., Han, Q., et al. (2018) · Stem Cells and Development · doi:10.1089/scd.2017.0296 · Cited by 232
Metadata
- Authors
- Cochain, C., Channon, K. M., & Silvestre, J.-S.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2013-03-20
- Volume
- 18
- Issue
- 9
- Pages
- 1100-1113
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2062121786
- Cited by
- 244
- References
- 10
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.